Improving the efficacy of anti-hair loss drug treatments with a cosmetic lotion containing caffeine, taurine and growth factors
Phase 4
Completed
- Conditions
- Androgenic alopecia in men or women (FAGA) candidate for specific drug treatment (i.e. topical minoxidil in men or women or oral finasteride in men)Skin and Connective Tissue Diseases
- Registration Number
- ISRCTN10404684
- Lead Sponsor
- Difa Cooper (Italy)
- Brief Summary
2022 Results article in https://doi.org/10.29011/2575-8268.100199 (added 31/05/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. Men and women >18 years of age
2. Suffering AGA or FAGA requiring drugs treatments (Norwood Hamilton AGA grade III-V)
Exclusion Criteria
1. Inflammatory scalp skin condition
2. AGA treatments (finasteride or minoxidil) in the previous 6 months
3. Iron deficiency anaemia
4. Seborrheic dermatitis or scalp psoriasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Evolution of alopecia using a 7-point Global Photographic Assessement Score (GPAS)(+3 Very good improvement,+2 good improvement;+1 mild improvement; 0: not an improvement; -1 mild worsening; -2 worsening; -3 severe worsening) in the group of GFM-DA treated subjects in comparison with the group of drugs treatment only.<br>2. GPAS was evaluated by comparing the standard photos taken at baseline visit, after 12 weeks and at week 24 by an investigator unaware of treatment arm allocation
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures